(Total Views: 105)
Posted On: 12/21/2020 10:40:48 AM
Post# of 21197
$NK News Article - ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate https://marketwirenews.com/news-releases/-xa0...69855.html
(0)
(0)
My Twitter: WhyteStocks
Scroll down for more posts ▼
